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AbsTRACT
Rationale Pulmonary rehabilitation (Pr) is an 
effective, key standard treatment for people with 
cOPD. nevertheless, low participant uptake, insufficient 
attendance and high drop- out rates are reported. 
investigation is warranted of the benefits achieved 
through alternative approaches, such as pulmonary tele- 
rehabilitation (PTr).
Objective To investigate whether PTr is superior to 
conventional Pr on 6 min walk distance (6MWD) and 
secondarily on respiratory symptoms, quality of life, 
physical activity and lower limb muscle function in 
patients with cOPD and FeV1 <50% eligible for routine 
hospital- based, outpatient Pr.
Methods in this single- blinded, multicentre, superiority 
randomised controlled trial, patients were assigned 1:1 
to 10 weeks of groups- based PTr (60 min, three times 
weekly) or conventional Pr (90 min, two times weekly). 
assessments were performed by blinded assessors at 
baseline, end of intervention and at 22 weeks’ follow- up 
from baseline. The primary analysis was based on the 
intention- to- treat principle.
Measurements and main results The primary 
outcome was change in 6MWD from baseline to 10 
weeks; 134 participants (74 females, mean±sD age 
68±9 years, FeV1 33%±9% predicted, 6MWD 327±103 
metres) were included and randomised. The analysis 
showed no between- group differences for changes in 
6MWD after intervention (9.2 metres (95% ci: −6.6 to 
24.9)) or at 22 weeks’ follow- up (−5.3 metres (95% ci: 
−28.9 to 18.3)). More participants completed the PTr 
intervention (n=57) than conventional Pr (n=43) (χ2 test 
p<0.01).
Conclusion PTr was not superior to conventional Pr 
on the 6MWD and we found no differences between 
groups. as more participants completed PTr, supervised 
PTr would be relevant to compare with conventional Pr 
in a non- inferiority design.
Trialregistration number
 clinicalTrials. gov( ncT02667171), 28 January 2016.
InTROduCTIOn
Pulmonary rehabilitation (PR) is recognised as an 
important, standard treatment for people with 
chronic obstructive pulmonary disease (COPD). 
PR is well documented to reduce symptoms and 
increase walking capacity and quality of life (QoL), 
but its effect on physical activity level (PAL) is 
limited.1–5 Despite the benefits, PR programmes 
are challenged by low participant uptake, insuf-
ficient attendance and high drop- out rates.6–9 
Barriers have previously been reported, including 
transportation issues, symptom severity, acute exac-
erbations, lack of energy and disruption of daily 
routines.6 8 10 11 Recently, the American Thoracic 
Society (ATS)/European Respiratory Society (ERS) 
recommended investigating alternative approaches 
to PR, such as tele- rehabilitation, in an attempt to 
increase uptake and make PR available to more 
patients.12 To date, two randomised controlled 
trials (RCTs) have explored the effect of unsuper-
vised web- based or video- demonstrated individual 
exercise and education compared with conventional 
group- based PR in patients with stable moderate- 
to- severe COPD.13 14 The studies did not find 
differences between interventions for outcomes of 
walking capacity and respiratory symptoms.13 14 
Key messages
What is the key question?
 ► Can a supervised pulmonary tele- rehabilitation 
programme, including structured exercise 
and education, deliver higher programme- 
adherence and thereby superior benefits to 
a conventional hospital- based pulmonary 
rehabilitation (PR) programme for patients with 
severe COPD?
What is the bottom line?
 ► This pulmonary tele- rehabilitation model 
demonstrated short- term and medium- term 
improvements in functional capacity and 
disease- related symptoms that were not 
superior to conventional hospital- based PR for 
patients with severely progressed COPD.
Why read on?
 ► Despite the benefits, PR programmes are 
challenged by low participant uptake, 
insufficient attendance and high drop- out 
rates; supervised pulmonary tele- rehabilitation 
may be a useful second- line option to improve 
access for patients with severe COPD who 
cannot participate in or comply with a 
conventional hospital- based PR programme.
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One study including patients with COPD and comorbid heart 
failure (NYHA II- IV) compared home- monitored exercise and 
weekly individual telephone supervision with usual care (no 
intervention). The intervention provided clinically relevant 
differences in walking capacity, respiratory symptoms and QoL 
compared with usual care. Furthermore per- protocol anal-
yses showed that the gains were maintained at the 2- month 
follow- up.15 Lastly, in patients with moderate COPD, one small 
RCT study (n=37) compared usual care (no intervention) with 
a supervised pulmonary tele- rehabilitation (PTR) programme in 
groups of two to four patients.16 This study showed significant 
and clinically relevant between- group difference on endurance 
shuttle walk, anxiety and depression symptoms and self- efficacy 
in favour of supervised PTR.16 All four studies are limited in 
their conclusions as none declared a priori- design (superior, 
equivalence, non- inferior) in the trial registry protocol, and just 
two studies stated a hypothesis.14 16 Although results from the 
recent PTR studies are promising, effects from supervised PTR 
in groups compared with conventional outpatient supervised 
PR in groups remain to be investigated. Consequently, evidence 
is needed to ascertain any possible effect of a fully supervised 
real- time PTR programme on relevant outcomes. To our knowl-
edge, our study is the first RCT investigating the short- term and 
medium- term effect of a supervised PTR programme compared 
with a supervised conventional PR programme on walking 
capacity, symptoms, QoL and PAL in patients with COPD, FEV1 
<50% and a high symptom burden eligible for routine hospital- 
based outpatient PR. We hypothesised that the supervised PTR 
programme would be superior to a supervised conventional PR 
regarding change in 6 min walk distance (6MWD) because of an 
expected higher adherence rate, leading to a greater response.17 
This paper reports on the clinical outcomes. A full economic 
analysis will be published separately.
MeThOds
Trial design and participants
We conducted a randomised clinical, assessor- blinded and 
statistician- blinded, superiority, multicentre trial with two 
parallel groups to investigate the effect of supervised PTR 
compared with conventional PR on walking capacity in patients 
eligible for outpatient hospital- based PR. Patients were recruited 
from the respiratory departments of eight different university 
hospitals in Greater Copenhagen during March 2016 to October 
2017. Inclusion and exclusion criteria corresponded to the 
criteria for outpatient hospital- based routine PR in the Capital 
Region of Copenhagen, Denmark, and pertained to adults with a 
clinical diagnosis of COPD defined as FEV1/FVC <0.70, FEV1 
<50%, Medical Research Council ≥2 and no participation in 
PR within 6 months of the start of intervention.17 18 All patients 
provided written and verbal informed consent.
Randomisation and blinding
After baseline assessments, patients were randomly allocated 1:1 
to receive PTR or conventional hospital- based PR. The alloca-
tion followed a computer- generated randomisation list made 
by a biostatistician for each recruiting hospital; treatment was 
denoted as A and B to ensure blinding of the biostatistician. A 
senior manager from an independent research department was 
responsible for the randomisation list and provided the draw to 
ensure concealment. All assessors were blinded to group allo-
cation, hypotheses and intervention details. Patients were not 
possible to blind for allocation. In the case of failure to keep the 
assessor blinded, a second assessor was available to conduct the 
blinded assessment on another day. The biostatistician had the 
main responsibility for the data analyses.
Intervention
Pulmonary tele-rehabilitation
The details and appropriate dosage set- up from both intervention 
programs are available in the online supplementary material and 
in our previously published protocol article.17 In brief, the PTR 
programme was designed by the study group and aligned with 
exercise intensities and education themes from conventional PR. 
It was a group- based, supervised and standardised programme 
performed by the patients in their homes three times weekly for 
10 weeks via a videoconference software system installed on a 
single touch screen. The exercise sessions lasted 35 min (weekly 
exercise volume 105 min) with incorporated warm- up and 
high repetitive time- based muscle endurance training followed 
by 5 min’ rest before beginning a patient education session of 
20 min (weekly education volume 60 min).
Conventional pulmonary rehabilitation
The conventional outpatient hospital- based PR programme was 
group- based, supervised and standardised and was performed 
twice a week for 10 weeks (in one hospital, for 12 weeks). The 
programme followed the Danish Health Authority’s National 
Clinical Guideline and the Regional Guidelines.17 19 20 The exer-
cise sessions lasted 60 min and incorporated warm- up, endurance 
and resistance training and a cool- down period (weekly exercise 
volume 120 min). The patient education sessions lasted 60 to 
90 min and took place once a week after the exercise session 
(detailed online supplementary available).
Outcomes
Full details on outcome, assessment procedures and quality 
control are available in the online supplementary material. 
Briefly, the primary outcome was change in the 6MWD on 
completion of the programme. Secondary outcomes were COPD 
Assessment Test (CAT), Hospital Anxiety and Depression Scale 
(HADS), EuroQol 5- Dimension Questionnaire (EQ- 5D), the 
30 s sit- to- stand test (30sec- STS), Clinical COPD Questionnaire 
(CCQ) and Physical Activity Level (PAL). The PAL was measured 
with activePAL triaxial accelerometer (PAL Technologies Ltd, 
Glasgow, UK) worn 24 hours for 5 days. PAL was measured 
on 73 patients residing within a radius of 25 km of Bispebjerg 
University Hospital. All assessment procedures were performed 
at baseline, end of intervention and at 22 weeks’ follow- up 
from baseline. The procedures were reproducible and have been 
published.21 Descriptive variables included body mass index, 
smoking status, medication and Charlson Comorbidity Index, 
spirometry and anthropometric measures, which followed the 
standardised protocols from the Danish Society of Respiratory 
Medicine.22 Adverse events, hospitalisations and deaths were 
recorded throughout the trial by the National Health Data 
Authorities.
statistical analysis
For the 6MWD, a change of 26 m is considered a minimal clin-
ically important difference (MCID) in patients with COPD and 
FEV1 <50%.23–25 Based on a two- sample independent t- test 
with an MCID of 26 m, a SD of 44.6 m,24 a power of 80%, a 
significance level of 0.05 and an anticipated drop- out rate of 
30%, 134 patients were recruited. Using this sample size, 
expected SD and existing MCID, power estimations for the 
secondary outcomes revealed 80% power to detect MCID in all 
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Table 1 Baseline characteristics
Variables All (n=134) PTR (n=67) PR (n=67)
Female sex, n (%) 74 (55) 35 (52) 39 (58)
Age, year 68.3 (9.0) 68.4 (8.7) 68.2 (9.4)
Body mass index, kg/m2 25.7 (5.8) 25.5 (5.0) 25.9 (6.4)
FEV1, % predicted 33.1 (9.4) 32.6 (10.3) 33.7 (8.4)
FEV1/FVC, % 43.3 (11.2) 43.9 (11.3) 42.7 (11.1)
GOLD I/II/III/IV, % 0/0/61/39 0/0/55/45 0/0/67/33
A/B/C/D, % 2/34/4/60 5/34/3/58 0/33/4/63
LTOT, n (%) 20 (15) 11 (16) 9 (13)
SpO2 at rest, % 94.6 (2.8) 94.6 (2.4) 94.8 (3.1)
MRC 1/2/3/4/5, n 0/2/65/50/17 0/2/30/27/8 0/0/35/23/9
Smoking status, n (%)
  Never 3 (2) 2 (3) 1 (1)
  Former 99 (75) 51 (79) 48 (72)
  Current 30 (23) 12 (18) 18 (27)
Pack- year history, mean (SD) 43.5 (20.2) 42.4 (23.1) 44.5 (17.3)
BODE index points, median (IQR) 5.0 (4–6) 5.0 (4–7) 5.0 (4–6)
Charlson Comorbidity Index 1/2/≥3, (%) 40/37/23 45/40/15 34/33/33
Exacerbations, previous 12 month, (median, IQR) 2 (0–3) 2 (0–4) 2 (1–3)
Current medication, n (%)
  SABA 112 (84) 56 (84) 56 (84)
  SABA + SAMA 11 (8) 6 (9) 5 (7)
  LABA 2 (1) 1 (1) 1 (1)
  LAMA 3 (2) 2 (3) 1 (1)
  LABA + LAMA 24 (18) 12 (18) 12 (18)
  LABA + ICS 8 (6) 5 (7) 3 (5)
  LABA + LAMA + ICS 93 (69) 45 (67) 48 (71)
  Oral steroids 2 (1) 2 (3) 0 (0)
Walking aid, walker/other, n (%) 27/18 (34) 14/9 (34) 13/9 (33)
Highest 6MWD, metre 327.3 (102.8) 322.3 (108.3) 332.3 (97.5)
Highest 30sec- STS, repetitions 9.8 (4.3) 9.9 (4.7) 9.6 (3.8)
Physical activity level*
  Daily step count, steps 3091 (2161) 2779 (1966) 3422 (2335)
  Time sedentary, min 1205 (133) 1244 (121) 1164 (134)
  Time active, min 235 (133) 196 (121) 276 (134)
CAT, score 20.1 (7.0) 19.8 (7.3) 20.4 (6.6)
HADS, score
  HADS- anxiety 6.3 (3.5) 6.8 (3.8) 5.9 (3.1)
  HADS- depression 4.3 (3.0) 4.5 (2.) 4.1 (3.1)
EQ- 5D, VAS score 52.7 (19.2) 51.5 (19.4) 53.9 (19.1)
EQ- 5D, index score 0.68 (0.16) 0.66 (0.20) 0.70 (0.12)
CCQ, score
  Symptoms 2.9 (1.2) 2.8 (1.2) 3.0 (1.2)
  Functional 2.9 (1.2) 2.8 (1.1) 3.0 (1.3)
  Mental 2.8 (1.4) 2.8 (1.5) 2.9 (1.4)
  Total 2.8 (0.9) 2.7 (0.9) 2.9 (1.0)
Data are presented as mean (SD) except where otherwise indicated.
*ActivePAL triaxial accelerometer worn by in total 73 patients (PTR/PR: 37/36). Any statistically 
significant difference between PTR and PR denoted *p<0.05.
A/B/C/D, risk stratification, airflow obstruction, dyspnea and exercise capacity; BODE index, body mass 
index; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; EQ- 5D, Euro- Qol 5- dimension; 
FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global initiative 
for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Score; ICS, inhaled 
corticosteroid; LABA, long- acting β2- agonist; LAMA, long- acting muscarinic antagonist; LTOT, long- 
term oxygen therapy; MRC, Medical Research Council; 6MWD, 6 min walk distance; PR, pulmonary 
rehabilitation; PTR, pulmonary tele- rehabilitation; SABA, short- action β2- agonist; SAMA, short- acting 
muscarinic antagonist; 30- sec STS, 30 s sit- to- stand test; SpO2, arterial oxygen saturation as measured 
by pulse oximetry; VAS, Visual Analogue Scale.
secondary outcomes except CCQ and PAL.17 Descriptive data 
for the PTR and conventional PR are presented as mean and 
SD for continuous variables and frequency for categorical vari-
ables. Differences between the intervention groups in change of 
primary and secondary outcomes (end of intervention - base-
line and 22 weeks’ follow- up - baseline) were analysed by mixed 
effect models. The models included adjustment for treatment 
group, age, sex, body mass index, FEV1, Charlson Comorbidity 
Index, smoking status and a random effect for hospital alloca-
tion. To account for possible regression to the mean effect, the 
baseline measure for the outcome was also included as a fixed 
effect variable in the models. Normal distribution of the model 
residuals was evaluated by Q- Q plots. All data are considered 
missing at random, using this with the likelihood- estimation 
in the mixed effect model, the ignorability assumption for the 
likelihood estimator is used to account for missing data in the 
model estimates26 (number of data sets is stated in tables 1 and 2 
and online supplementary tables S2 and S3). Group differences 
on number of patients remaining in their programmes for the 
full intervention period, adherence, hospitalisation and death 
were analysed with χ2 test. Adherence/attendance was defined 
as a patient participating in an entire scheduled exercise and 
education session. Analysis of age and sex differences between 
patients with and without outcome measures was done by χ2 and 
Wilcoxon rank- sum test. Per- protocol analysis included patients 
attending ≥70% of the planned sessions. Statistical analyses 
were carried out using R 3.2.2 (R Foundation for Statistical 
Computing, Vienna, Austria). P values of less than 0.05 were 
considered statistically significant.
ResulTs
Recruitment
Of the patients suitable for hospital- based PR, 1099 met the 
inclusion criteria and were considered; 714 patients refused PR 
and were thus deemed ineligible. Of 385 eligible patients, the 
majority (n=251) wished to undertake conventional PR and 
declined participation in the study. One hundred and thirty- 
four patients provided informed consent and were randomised 
(n=67 in each group) (figure 1). Baseline characteristics are 
shown in table 1.
Primary outcome
Tables 2 and 3 show the differences between and the changes 
within the groups at the end of PR/PTR and at the 22 weeks’ 
follow- up from baseline. We found no statistically significant 
between- group difference for change in the 6MWD after inter-
vention (table 2). Both groups demonstrated statistically signifi-
cant improvements in the 6MWD after intervention, but the gain 
was sustained and significant only in the PTR group at 22 weeks’ 
follow- up from baseline (table 3). None of the group improve-
ments exceeded the MCID at any measurement time point.
secondary outcomes
The between- group difference for changes in respiratory symp-
toms (CAT) was statistically different at the end of intervention 
with a greater symptom reduction difference of −1.6 points 
(p=0.04) in the PTR group that did not exceed the MCID 
(table 2). There was no between- group difference at the 22 weeks’ 
follow- up from baseline. The groups did not exceed the MCID in 
respiratory symptom reduction at any measurement time point 
(table 3). The PTR group had a statistically significant reduc-
tion in anxiety and depression scores (HADS- A and HADS- D) 
compared with the conventional PR group after intervention, 
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Table 2 Between- group differences in primary and secondary outcomes in PTR and PR groups. Intention- to- treat principle
between- group differences from baseline (95% CI)
PR- PTR (unadjusted) PR- PTR (adjusted)
end rehabilitation† 22 weeks from baseline‡ end rehabilitation† 22 weeks from baseline‡
Primary outcome
  6MWD, min 6.3 (−9.8 to 22.5) −11.0 (−34.4 to 12.4) 8.3 (−7.7 to 24.3) −3.9 (−27.9 to 19.9)
Secondary outcomes
  30sec- STS, reps 0.5 (−0.6 to 1.5) 0.4 (−0.7 to 1.4) 0.5 (−0.6 to 1.5) 0.5 (−0.6 to 1.6)
  CAT, points 1.4 (−0.1 to 3.0) −0.5 (−2.6 to 1.5) 1.6 (0.1 to 3.3)* −0.2 (−2.1 to 1.8)
HADS
  Anxiety, points 1.1 (0.1 to 2.1)* 0.2 (−0.9 to 1.4) 1.2 (0.2 to 2.3)* 0.4 (−0.8 to 1.6)
  Depression, points 0.7 (−0.1 to 1.5) −0.2 (−1.3 to 1.0) 0.9 (0.1 to 1.7)* −0.2 (−1.3 to 1.0)
  EQ- 5D- VAS, points −0.2 (−6.4 to 5.9) 0.8 (−5.8 to 7.5) −0.2 (−6.2 to 5.9) 1.6 (−5.1 to 8.3)
CCQ
  Function, points 0.1 (−0.2 to 0.5) 0.1 (−0.2 to 0.5) 0.1 (−0.2 to 0.5) 0.2 (−0.2 to 0.5)
  Mental, points 0.1 (−0.3 to 0.6) −0.1 (−0.4 to 0.3) 0.3 (−0.2 to 0.7) 0.1 (−0.3 to 0.5)
  Symptoms, points 0.2 (−0.1 to 0.5) 0.1 (−0.3 to 0.5) 0.2 (−0.1 to 0.5) 0.1 (−0.2 to 0.5)
  Total, points 0.2 (−0.1 to 0.4) 0.1 (−0.2 to 0.3) 0.2 (−0.1 to 0.5) 0.1 (−0.1 to 0.4)
PAL
  Steps per day −283 (−845 to 278) −302 (−1035 to 419) −436 (−1010 to 138) −103 (−886 to 597)
  Sedentary, min 9.4 (−35.2 to 51.3) 8.6 (−53.8 to 36.6) 7.7 (−49.0 to 52.2) 14.6 (−32.5 to 58.5)
  Active, min −9.4 (−51.3 to 35.4) −8.6 (−36.6 to 53.8) −7.7 (−52.2 to 49.0) −14.6 (−58.5 to 32.5)
Data are mean difference (95% CI).
*P value for group mean change differences <0.05.
†Complete observations (n) used for the likelihood estimate from end of rehabilitation to baseline (total): 6MWD: (115); 30sec- STS: (115); CAT: (119); HADS: (110); EQ- 5d- VAS: 
(119); CCQ: (119); PAL: (59).
‡Complete observations (n) used for the likelihood estimate from 22 weeks’ follow- up from baseline to baseline (total): 6MWD: (95); 30sec- STS: (95); CAT: (106); HADS: (100); 
EQ- 5d- VAS: (104); CCQ: (106); PAL: (55).
CAT, COPD Assessment Test; CCQ, COPD Clinical Questionnaire; EQ- 5D, EuroQol 5- Dimension Questionnaire; HADS, Hospital Anxiety and Depression Scale; 6MWD, 6 min walk 
distance; PAL, physical activity level; PR, pulmonary rehabilitation; PTR, pulmonary tele- rehabilitation; 30sec- STS, 30 s sit- to- stand test; VAS, Visual Analogue Scale.
but it did not exceed the MCID. There were no between- group 
differences at the 22- week follow- up (table 2). The within group 
improvements on the anxiety domain were significant for the 
PTR group after intervention but did not exceed the MCID and 
the improvement was not sustained at the 22- week follow- up. 
No group exceeded the MCID for QoL (EQ- 5D- VAS) and lower 
limb muscle function (30sec- STS) (table 3). We registered a 
statistically significant decrease in number of daily steps per day 
in the PR group from baseline to end of intervention and to 
the 22- week follow- up, whereas daily steps per day remained 
unchanged in the PTR group (table 3). There was no difference 
between groups in the per- protocol analyses in any outcome at 
any measurement time point (see online supplementary tables 
S2 and S3).
The attendance rate was a median of 25 session (IQR: 20 to 
28) in the PTR group and 16 session (IQR: 8 to 19) in the PR 
group and thus the exercise volume was a median of 750 min 
(IQR: 600 to 840) in the PTR group and 960 min (IQR: 480 to 
1140) in the PR group. A significantly higher number of patients 
remained in the PTR programme for the full intervention period 
compared with the PR programme (PTR: 57/67 vs PR: 43/67; 
OR: 3.18 (95% CI: 1.37 to 7.35), p<0.01). However, there was 
no difference between groups for those who attended ≥70% of 
the programs’ total sessions, (PTR: 49/67 vs PR: 42/67; OR: 
1.68 (95% CI: 0.78 to 3.37), p<0.27). The mean adherence rate 
among drop- outs who attended at least one session was 50% of 
all sessions (IQR%: 42 to 64) in the PTR programme versus 
33% of all sessions (IQR%: 18 to 49) in the PR programme. 
Two drop- outs, both in the PR group, were potentially related 
to adverse effects of the PR programme. Both events were 
related to overload with subsequent pain in the knee and groin, 
respectively, and did not require medical treatment. In total, 
41 hospital admissions related to COPD exacerbations were 
recorded (PTR: n=21; PR: n=20; p=0.77) during the rehabil-
itation period, and 74 hospitalisations related to COPD exacer-
bations (PTR: n=38; PR: n=36; p=0.97) were recorded at the 
22- week follow- up (see the online supplementary S for diag-
nostic codes used in the registry from the National Health Data 
Authorities and online supplementary S5 for hospital days and 
outpatient visits). There was no significant difference between 
groups for all cause hospitalisations during rehabilitation. Three 
deaths (PTR: n=1; PR: n=2) occurred during the rehabilitation 
period, and another three had died at the 22- week follow- up 
(p=1.0).
No difference could be shown between patients with and 
without missing outcome measurement on sex, all p values 
>0.07. By contrast, the median age was significantly higher 
among patients with missing values for 6MWD, 30sec- STS, 
repetitions and CCQ mental score.
Registered problems with the technical solution
Major technical issues leading to cancellation and rescheduling 
of group sessions affected 2 of 360 group sessions. Minor tempo-
rary technical issues (ie, sound artefacts, screen freezes) not 
leading to cancellation or delay were present in 14% of the total 
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Figure 1 Consolidated Standards of Reporting Trials diagram. AMA, Amager; BBH, Bispebjerg; Disc, discogenic issue; FBH, Frederiksberg; FSH, 
Frederikssund; GEH, Gentofte; HEH, Herlev; HIL, Hillerød; HVH, Hvidovre; MI, myocardial infarction; OA, osteoarthritis; PR, pulmonary rehabilitation; 
PTR, pulmonary tele- rehabilitation, RCT, randomisedcontrolled trial.
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Table 3 Within- group changes in primary and secondary outcomes in PTR and PR groups. Intention- to- treat principle
Within- group changes from baseline (95% CI)
PTR (n=67) PR (n=67)
end rehabilitation† 22 weeks from baseline‡ end rehabilitation† 22 weeks from baseline‡
Primary outcome
  6MWD, min 17.2 (5.8 to 28.5)* 22.0 (5.0 to 39.1)* 23.5 (12.1 to 35.0)* 11.0 (−5.2 to 27.2)
Secondary outcomes
  30sec- STS, reps 1.3 (0.4 to 2.0)* 1.1 (0.1 to 2.0)* 1.7 (0.9 to 2.5)* 1.5 (0.5 to 2.3)*
  CAT, points −1.7 (−3.2 to −0.2)* −0.5 (−1.9 to 1.1) −0.3 (−1.8 to 1.2) −1.0 (−2.5 to 0.6)
HADS
  Anxiety, points −1.0 (−1.7 to −0.2)* −0.5 (−1.4 to 0.5) 0.1 (−0.6 to 0.8) −0.3 (−1.2 to 0.7)
  Depression, points −0.4 (−1.1 to 0.3) 0.5 (−0.4 to 1.5) 0.3 (−0.4 to 1.0) 0.3 (−0.6 to 1.4)
  EQ5D- VAS, points 3.2 (−1.2 to 7.6) 3.5 (−1.2 to 8.2) 2.9 (−1.4 to 7.2) 4.2 (−0.4 to 9.0)
CCQ
  Function, points −0.3 (−0.5 to −0.1)* 0.1 (−0.1 to 0.4) −0.1 (−0.4 to 0.1) 0.1 (−0.2 to 0.5)
  Mental, points −0.2 (−0.6 to 0.1) −0.1 (−0.5 to 0.3) −0.1 (−0.4 to 0.2) −0.1 (−0.4 to 0.3)
  Symptoms, points −0.3 (−0.6 to −0.1)* −0.2 (−0.5 to 0.1) −0.2 (−0.4 to 0.1) 0.1 (−0.3 to 0.5)
  Total, points −0.3 (−0.4 to −0.1)* 0.0 (−0.2 to 0.2) −0.1 (−0.3 to 0.1) 0.1 (−0.2 to 0.3)
PAL
  Steps per day −116 (−503 to 270) −292 (−852 to 307) −400 (−803 to −2.3)* −594 (−1164 to −57)*
  Sedentary, min 29.0 (−29.9 to 95.4) 18.8 (−11.8 to 49.3) 38.3 (−21.7 to 107.3) 10.1 (−21.0 to 41.3)
  Active, min −29.0 (−95.4 to 29.9) −18.8 (−49.3 to 11.8) −38.3 (−107.3 to 21.7) −10.1 (−41.3 to 21.0)
Data are mean difference (95% CI). Estimates adjusted for baseline outcome measure. Estimates calculated for baseline measure equal to the mean baseline measure for study 
population.
*P value within group changes <0.05.
†Complete observations (n) used for the likelihood estimate from end of rehabilitation to baseline (PTR/PR): 6MWD: (56/59); 30- sec STS: (56/59); CAT: (59/62); HADS: (53/57); 
EQ5d- VAS: (57/62); CCQ: (57/62); PAL: (30/29).
‡Complete observations (n) used for the likelihood estimate from 22 weeks’ follow- up from baseline to baseline (PTR/PR): 6MWD: (44/51); 30sec- STS: (44/51); CAT: (53/53); 
HADS: (50/50); EQ5d- VAS: (51/53); CCQ: (53/53); PAL: (28/27).
CAT, COPD Assessment Test; CCQ, COPD Clinical Questionnaire; EQ- 5D, EuroQol 5- Dimension Questionnaire; HADS, Hospital Anxiety and Depression Scale; 6MWD, 6 min walk 
distance; PAL, physical activity level; PR, pulmonary rehabilitation; PTR, pulmonary tele- rehabilitation; 30sec- STS, 30 s sit- to- stand test; VAS, Visual Analogue Scale.
group session (49/360). Individual patient cancellation caused 
by technical problems was 12 of 1902 individual connections.
dIsCussIOn
The main finding of this multicentre, single- blinded, 
randomised clinical trial was that supervised PTR was not 
superior to conventional hospital- based PR regarding walking 
capacity (6MWD). More patients completed PTR than 
PR, whereas, contrary to our pre- hypothesis, there was no 
between- group difference in adherence rate (attending ≥70% 
of the planned sessions).
To our knowledge, the effects of a supervised PTR programme 
compared with a supervised conventional PR programme have 
not been previously investigated. Tsai et al found a clinically 
relevant effect on 6MWD and endurance shuttle walk test 
(ESWT) from supervised PTR compared with no interven-
tion.16 The study by Bernocchi et al15 including patients with 
both COPD and heart failure reported superiority on 6MWD 
from an individual home- monitored exercise programme with 
a weekly phone call compared with no intervention; the inter-
vention group exceeded the MCID and maintained the gain 
at the 2- month follow- up.15 The studies by Bourne et al13 and 
Chaplin et al14 compared the effect of unsupervised web- based 
or video- demonstrated individual exercise and education with 
conventional group PR and found comparable between- group 
effects on walking tests and within- group changes that exceeded 
the MCID for 6MWD and ESWT but not for incremental shuttle 
walk test.13 14
By contrast, we found that neither conventional PR nor PTR 
improved the 6MWD above the MCID. Differences in popu-
lation characteristics could in part explain our negative result. 
Compared with the above- mentioned studies, patients in our 
cohort had lower FEV1, higher symptom burden, more exacer-
bations, lower walking capacity and most likely more locomotor 
disadvantages because in our study, 34% used a walking aid. Use 
of a walking aid or other indications of frailty have not been 
reported in the previous PTR studies.13–16 We recruited patients 
with identical real- world inclusion criteria for hospital- based 
PR, which could limit the consistency and efficacy of the results; 
however, our study reflects routine practice. Recently, two 
large RCTs by Holland et al27 and Horton et al28 including in 
total 453 patients with COPD, compared home- based PR with 
supervised centre- based PR, using a pragmatic trial design, also 
failed to achieve the expected MCID on walking capacity from 
both interventions. Finally, a retrospective cohort study of 2068 
patients with COPD of differing severity and with different 
characteristics receiving gold standard outpatient or inpatient 
PR in the Netherlands reported that only 40% to 50% of all 
patients exceeded the MCID for 6MWD, HADS- A, HADS- D 
and St George's Respiratory Questionnaire, while the group 
average improvement almost exceeded the MCID.29 In this 
study, Spruit and colleagues demonstrated that patients respond 
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very heterogeneously on both the physical and self- reported clin-
ical outcomes. This suggests the need for reconsideration of the 
assumption that all patients with COPD are likely to respond 
similarly and sufficiently to specific and restricted primary 
outcomes in either conventional PR programs29 or alternative 
home- based programs.27 28
From the Cochrane review it appears that 43% of the larger 
studies (including more than 30 participants in each group) 
did not exceed the MCID for the 6MWD1 and, importantly, 
meta- epidemiological studies have shown that single- centre 
trials yield 14% to 27% larger effect sizes than do multicentre 
trials even when analyses are adjusted for sample size and 
bias.30
The completion rate in our study was significantly higher 
in the PTR group than in the PR group; however, we did not 
find a significant higher adherence rate in the PTR group (73%) 
compared with the PR group (62%). The drop- out rate of 
36% in the PR group was anticipated and comparable to other 
studies reporting drop- out rates from 10% to 50%.6 7 11 27 28 31 
The annual 2018 data audit from the Danish Regional Quality 
Database in COPD revealed that 45% of all participants in 
Danish outpatient hospital PR adhere to less than 50% of the PR 
program.32 The real- world data from this quality database reflect 
the challenges with adherence in a conventional hospital- based 
real- world PR programme and should be contrasted with the 
distinctly higher adherence in the PTR programme, where 73% 
of patients attended ≥70% of the sessions. Thus, PTR seemingly 
has the potential to overcome some barriers to adherence and 
completion. It should be noted that only one- third of patients 
eligible for this study were willing to participate in this RCT 
as they stated ‘preferring conventional PR’, thus limiting the 
external validity (figure 1). Patient preferences and motivation 
have a potential impact on the outcomes achieved in different 
settings. This indicates that PTR could be an alternative for 
some patients eligible for outpatient hospital- based PR. As the 
134 patients who agreed to participate may be particularly moti-
vated, the 608 patients who declined participation in conven-
tional PR would be an important group of interest for future 
research in the field of exploring the relevance and effects of 
PTR as an alternative delivery model.
There were also a number of important secondary find-
ings in the present study. We investigated a cohort of patients 
with an extremely low level of physical activity, with average 
steps per day corresponding to basal and limited activity, 
for example, getting out of bed, making a meal and infre-
quent walks outside the home. This low and unchanged PAL 
throughout the study could affect the outcome and explain 
why the MCID in 6MWD was not exceeded since PAL and 
steps above 7500 per day are considered essential for physical 
functioning and overall health.33
We found that the PTR group had a significant reduction in 
CAT, anxiety and depression scores (HADS- A and HADS- D) 
compared with the PR group after intervention; however, the 
reduction did not exceed the MCID and the difference was not 
persistent at the 22- week follow- up. The higher completion 
rate in the PTR group, where patients continued to receive real- 
time attention and care, could be a plausible explanation of the 
differences after intervention. The previously mentioned PTR 
studies by Chaplin et al14 and Bourne et al13 did not find any 
between- group differences in HADS after intervention, while 
Tsai et al16 found differences identical to ours with supervised 
PTR compared with no intervention. The impact of real- time 
supervision versus the web- based PTR, including the means of 
communication, is not possible to quantify but could potentially 
explain some of these inconsistent findings between the PTR 
studies.
We are not aware of any studies comparing non- supervised 
PTR with supervised PTR. Ability to navigate and interact 
independently on a tablet and a webpage was required in 
the non- supervised PTR studies, whereas for the patients in 
our study, it was sufficient to have naive technical ability and 
skills.13 14 17 Essentially, future tele- rehabilitation designs must 
include specific considerations regarding delivery form and 
content and technical skills of the targeted population, partic-
ularly if PTR is to be considered as an extended offer specifi-
cally to those who live remotely and to those who lack energy 
and resources to join a conventional PR programme.
The strengths of this study include the multicentre design, 
rigorous methodology, powering for an adequate sample size to 
test our a priori hypothesis and the intention- to- treat analysis, 
which limits the risk of bias. We recruited patients with severely 
progressed COPD using national inclusion and exclusion criteria 
identical to routine clinical practice for conventional outpatient 
hospital- based PR. Blinding was also a strength of the present 
study. Our assessment of outcomes was performed with docu-
mented small and acceptable measurement errors.21 A limitation 
of the study concerns the small but real variation in exer-
cise content and volume among the seven hospitals delivering 
conventional PR, which was not possible to monitor and align. 
However, this is a true reflection of the real- world setting and 
thereby a real- world comparison. Different practical challenges 
to modelling, staffing and structuring PTR and differing patient 
acceptance of PTR in different countries, geographical regions 
and different types of healthcare system are limitations of the 
generalisability of our findings.
Proper organisation of PTR remains a challenge. It is a deli-
cate balance in terms of decision- makers not limiting access to 
outpatient conventional PR and replacing it with PTR to save the 
costs related to buildings, equipment, transportation, etc, while 
endeavouring to provide an option for patients who are unable 
to attend the outpatient programme. From our perspective, 
many research questions remain unanswered regarding PTR. 
Future research should address subjects such as which patients 
are best suited to PTR and how we accommodate the increasing 
focus on personalised training. We need to find ways to enhance 
digital literacy among elderly, frail patients and discover whether 
the supervised or web- based tele- model is more effective as well 
as cost- effective. Furthermore, it is not yet known if applications 
will be as as good as online groups with videoconferencing. 
Other aspects include the role of monitoring PTR and the 
long- term health- related and QoL- related outcomes. Another 
issue regarding future studies of both PR and PTR concerns 
the measured outcomes of interest. As results to date regarding 
the traditional exercise and QoL outcomes are not convincing 
in patients with severe disease status, it is necessary to try a 
different approach. Outcomes that embrace activities of daily 
living and/or reduce symptoms such as dyspnoea and fatigue are 
warranted. In the study by Spruit et al29 a composite endpoint 
for response to a 40- session PR programme was constructed and 
patients were clustered according to response profile. Interest-
ingly, those in the ‘very good responder’ cluster were charac-
terised by a worse baseline health status in comparison with the 
other clusters. However, it was unclear whether this multidi-
mensional response was driven by a single outcome measure or 
several measures, thus calling for further research in the context 
of composite outcomes.
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COnClusIOn
In conclusion, supervised PTR was not superior to super-
vised conventional PR in increasing 6MWD. Improvements in 
completion of PTR compared with PR were found; however, 
future non- inferiority studies of the 6MWD for PTR and PR are 
needed to justify recommending PTR based on better adherence 
to the programme.
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